HBV

Hepatitis B virus

HBV

Related Products

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

HBV Related Products (371)
Antibodies (2)

By Effects:	Inhibitors (335)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-109014

Tenofovir exalidex	Inhibitor	99.82%
Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC₅₀s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV.

HY-147255

Canocapavir	Inhibitor	98.91%
Canocapavir (ZM-H1505R) is an orally active HBV core protein-targeting antiviral agent. Canocapavir binds to the hydrophobic pocket at the dimer-dimer interface of HBV core protein (HBc), stimulating intracellular accumulation of nonfunctional HBV capsids, disrupting viral replication. Canocapavir interferes with the interaction between HBc and HBV large surface protein, resulting in diminished production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection.

HY-N0680R

Thiamine hydrochloride (Standard)	Inhibitor
Thiamine (hydrochloride) (Standard) is the analytical standard of Thiamine (hydrochloride). This product is intended for research and analytical applications. Thiamine hydrochloride (Thiamine chloride hydrochloride) is an essential micronutrient needed as a cofactor for many central metabolic enzymes.

HY-109195

Vebicorvir	Inhibitor	99.43%
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC₅₀s from 1.84 μM to 7.3 μM.

HY-157993

SAG-524	Inhibitor	98.50%
SAG-524 is a potent oral small molecule HBV viral replication inhibitor. SAG-524 decreased HBV-DNA and HbsAg levels in supernatant of HepG2.2.15 cells, IC₅₀ 0.92 and 1.4 nM, respectively.

HY-148560A

trans-ccc_R08	Inhibitor	99.71%
trans-ccc_R08 (Compound 1-B) is a cccDNA inhibitor with anti-HBV activity, with an IC₅₀ of 0.14 μM for HBeAg and an IC₅₀ of 0.08 μM for HBsAg in in vitro assays. trans-ccc_R08 inhibits covalently closed circular DNA (cccDNA). trans-ccc_R08 is applicable to research related to hepatitis B virus infection.

HY-145638A

Xalnesiran sodium	Inhibitor
Xalnesiran (RO7445482) sodium is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome. Xalnesiran sodium can be used for the research of chronic hepatitis B infection.

HY-107902

RIG-1 modulator 1	Inhibitor	99.54%
RIG-1 modulator 1 (Compound of claim 13) is an anti-viral compound which can be used against viral infections including influenza virus, HBV, HCV and HIV.

HY-100028

AT-130	Inhibitor	98.39%
AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC₅₀ of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells.

HY-N0854

Alisol F	Inhibitor	99.89%
Alisol F is a protostane-type triterpenoid with anti-inflammatory and anti-hepatitis B virus activities. Alisol F inhibits LPS (HY-D1056)-induced phosphorylation of ERK, JNK, p38, STAT3 and NF-κB (p65), suppresses the production of NO, IL-6, TNF-α and IL-1β, and also downregulates the levels of iNOS and COX-2. Alisol F reduces the serum alanine aminotransferase and aspartate aminotransferase levels in mice with acute liver injury and ameliorates their liver pathological damage.

HY-145579

Linvencorvir	Inhibitor	98.14%
Linvencorvir (RG7907) is an orally active Hepatitis B virus core protein allosteric modulator. Linvencorvir induces Apoptosis. Linvencorvir has antiviral activity against HBV.

HY-137453

Tenofovir amibufenamide	Inhibitor	99.67%
Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study.

HY-145592

Ruzotolimod	Inhibitor	99.92%
Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2.

HY-13782R

Tenofovir Disoproxil fumarate (Standard)	Inhibitor
Tenofovir Disoproxil (fumarate) (Standard) is the analytical standard of Tenofovir Disoproxil (fumarate). This product is intended for research and analytical applications. Tenofovir Disoproxil fumarate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B.

HY-112142

AB-423	Inhibitor	99.31%
AB-423 is an inhibitor of HBV capsid assembly, and potent inhibits HBV replication with EC₅₀/EC₉₀ of 0.08-0.27 μM/0.33-1.32 μM in cells.

HY-P99608

Exbivirumab	Inhibitor
Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant.

HY-P3601

Brain Derived Basic Fibroblast Growth Factor (1-24)	Inhibitor	98.01%
Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24) is a synthetic peptide, shows anti-bacterial and anti-HBV activities. Brain Derived Basic Fibroblast Growth Factor (1-24) can be used in infection disease and immune disease research.

HY-120377

CYP1A1 inhibitor 8a	Inhibitor	98.00%
CYP1A1 inhibitor 8a is a compound that potently and selectively inhibits the CYP1A1 enzyme and has the potential to prevent cancer. CYP1A1 inhibitor 8a exhibits more than 10-fold selectivity for CYP1A1 and more than 100-fold selectivity over other enzymes in the CYP1 subfamily. CYP1A1 inhibitor 8a can effectively antagonize B[a]P-mediated activation of the aryl hydrocarbon receptor (AhR) in yeast cells and protect human cells from CYP1A1-mediated B[a]P toxicity. CYP1A1 inhibitor 8a has the potential to be developed as a cancer chemopreventive agent.

HY-N10543

5-O-(E)-p-Coumaroylquinic acid	Inhibitor	99.86%
5-O-(E)-p-Coumaroylquinic acid, a quinic acid derivative, is a potent phytochemical agent against hepatitis B virus.

HY-149158

CCC-0975	Inhibitor	99.49%
CCC-0975 is a hepatitis B virus (HBV) inhibitor (EC₅₀=10 μM). CCC-0975 interferes with the conversion of relaxed circular DNA (rcDNA) to cccDNA, synchronously reducing cccDNA and its precursor deproteinized rcDNA (DP-rcDNA) without promoting their intracellular degradation. CCC-0975 is promising for research of chronic hepatitis B.

Name
Email *

	Sorry, but the email address you supplied was invalid.

HBV

HBV

HBV Related Products (371)

Antibodies (2)

HBV Related Products (371):